Evidence map›Paper›PMID 42776260›Full record

ArticleMedical microbiology and immunology2026

Interferon-γ-response to mycobacterial glycopeptidolipids in patients with pulmonary non-tuberculous mycobacterial infection.

Mathis Steindor, Sophia Dachmann, Florian Stehling, Margarete Olivier, Jan Kehrmann, Peter A Horn, Raquel Villar-Hernández, Svenja Straßburg, Matthias Welsner, Sivagurunathan Sutharsan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical microbiology and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mathis SteindorPediatric Pulmonology and Sleep Medicine, Children's University Hospital Essen, University of Duisburg-Essen, Essen, Germany. mathis.steindor@med.uni-duesseldorf.de.ORCID https://orcid.org/0000-0003-2724-5297
Sophia DachmannPediatric Pulmonology and Sleep Medicine, Children's University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Florian StehlingPediatric Pulmonology and Sleep Medicine, Children's University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Margarete OlivierPediatric Pulmonology and Sleep Medicine, Children's University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Jan KehrmannInstitute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Peter A HornInstitute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Raquel Villar-HernándezGenome Identification Diagnostics (GenID) GmbH, Straßberg, Germany.
Svenja StraßburgDepartment of Pulmonary Medicine, Adult Cystic Fibrosis Center, University Hospital Essen- Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Matthias WelsnerDepartment of Pulmonary Medicine, Adult Cystic Fibrosis Center, University Hospital Essen- Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Sivagurunathan SutharsanDepartment of Pulmonary Medicine, Adult Cystic Fibrosis Center, University Hospital Essen- Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Monika LindemannInstitute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The understanding of host responses to pulmonary infection with non-tuberculous mycobacteria (NTM) is incomplete and immunodiagnostic tools are not established. Unlike mycobacteria of the Mycobacterium tuberculosis complex, several NTM express glycopeptidolipids (GPLs) in their cell wall. Here, we investigate the interferon-γ response to mycobacterial GPLs and its diagnostic use in patients with pulmonary NTM infection. M. avium-derived GPLs were used for in vitro stimulation of peripheral blood mononuclear cells in an ELISpot assay of patients with pulmonary NTM infection and 3 control groups, (1) patients with tuberculosis (TB), (2) patients with cystic fibrosis without evidence of NTM infection (CF) and (3) healthy controls (HC). Immune responses were compared between the groups and for the subgroup of NTM patients with either M. avium complex (MAC) or M. abscessus complex (MABC). Interferon-γ responses of 31 patients with NTM (16 MABC, 11 MAC, 1 MABC & MAC, and 3 other NTM) were compared to 43 controls (15 TB, 15 CF, 13 HC). Responses to GPLs were significantly stronger in the NTM group compared to controls (13.5 vs. 1.5 spots per 300,000 PBMC, p < 0.0001, data represent median values). MAC patients had an overall stronger reaction than MABC patients. Assay sensitivity and specificity were 64 and 98% for MAC, 19 and 95% for MABC, and 32 and 98% for all NTM, respectively. Mycobacterial GPLs are potent drivers of interferon-γ-responses. Patients with pulmonary NTM infection show stronger immune responses to GPLs compared to uninfected participants, making GPLs a promising target for the development of NTM immune diagnostic tools.

Indexed as

GlycolipidsGlycopeptidesInterferon-gammaMycobacterium Infections, NontuberculousNontuberculous MycobacteriaAdultAgedEnzyme-Linked Immunospot AssayFemaleHumansLeukocytes, MononuclearMaleMiddle AgedMycobacterium avium ComplexYoung AdultGlycolipidsGlycopeptidesInterferon-gammaCystic fibrosisDiagnostic toolImmune responseNon-tuberculous mycobacteriaPulmonary disease

Identifiers

PMID42776260
PMCPMC13601140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.